KeyBanc lowered the firm’s price target on Inspire Medical (INSP) to $234 from $236 and keeps an Overweight rating on the shares after the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $231.12, a high ...

KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Inspire Medical Systems (INSP – Research Report), with a ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday.

Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA ...

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 4.1% of Inspire Medical Systems ...

Inspire Medical (TASE: PMCN )'s fourth quarter revenue represents a roughly 25% increase compared to the same quarter of the previous year, while the anticipated full-year 2024 revenue of $802.6 ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday. Despite the robust preliminary results, the company’s shares plunged nearly ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...